2002 91 1 1 WTO 144 WTO WTO WTO 1
2
3 WTO 1956 1958 1895-1945
WTO WTO WTO SWOT 4
Strategy Strategos 1947Von Neumann Morgenstern Theory of Games 2-1 2 1 Von Neumann 1947 Morgenstern Ducker 1954 5
Chandler 1962 Tiller 1963 Ansoff 1965 / Kotler 1967 Cannon 1968 Andrews 1969 Vancil 1970 NewmanLogan 1976 Rogers 1977 McNichols 1977 Mintzberg 1978 Galbraith Nathanson 1978 HoferShendel 1979 Quinn 1980 Glueck 1980 1981 1984 Cool 1985 Steiss 1985 RueHolland 1986 6
Fred 1989 1994 Hill 1995 Porter 1996 2000 1999 9 7 2-1 2000 SWOT 2-1 7
8 Michael Porter 2-2 1.
2. 3. 4. 5. - 9
2-2 Porter Michael E. Porter.1979,"How Competence Forces Shape Strategy". Harvard Business Review, March- April. Michael E Porter 2-3 10
Porter, M. E.1985,Competitive Strategy, New York: The Free Press. p.37 1. Primary Activities 1 2 3 4 2-3 Porter 11
12 5 2. Support Activities 1 2 3 4
() SWOT Ansoff 1965 SWOT strengths weakness opportunities threats SWOT SWOT Aaker SWOT Barney SWOT Michael E. Porter 13
Barney 2-4 Barney. D.F.1991,"Tine paths in the diffusion of Product Innovations". Macmillan, London. P.100 1982Weihrich (strengths) (weakness) (opportunities) (threats) SO (Max- Max) 14
ST (Max- Min) WO (Min- Max) WT (Min- Min) (S) (W) (O) SO WO (Max-Max) (Min-Max) (T) ST WT (Max-Min) (Min-Min) 2-5 SWOT Weihrich H.1982,"The TOWS Matrix-A Tool for Situational Analysis". Long Range PlanningVol.15,No.2, p.60 Ansoff (1965) 15
Miles & Snow (19781984) Porter (1980) (1984) Miller (1986) Ansoff (1965) 1. 2. 3. 4. 16
2-2 Ansoff Ansoff. I. H.1988, The New Corporate Strategy,3 rd ed., New York NJohn Wiley & Sons, Inc., p.83 Miles & Snow (19781984) Miles & Snow 1. (Defenders)2. (Prospectors)3. (Analyzers)4. (Reactors) 1. (defenders) 2. (prospectors) 17
18 3. (analyzers) 4. (reactor) Porter (1980) Porter 1. (Differentiation)
19 2. (Cost Leadership) 3.
2-6 Porter Porter, M. E.1985,Competitive Strategy, New York: The Free Press. p.39 (1984) 1. 2. 3. 20
4. 2-7 1984 Miller (1986) Porter Miller (1986) 1. (Product Innovation) 2. (Market Differentiation) 21
3. (Market Scope) 4. (Cost Control) WTO GATT 1995 1 1 144 95 GATT 46 GATT Uruguay Round1986-1994 117 1994 4 15 Marrakeh 1995 1 1 WTO WTOWTO 22
23 2-3 1945 ITO) 19458 1946 19473 ITO GATT 19471031 ITO GATT 199511 117 199445 405 35
24 WTO WTO WTO WTO WTO WTO
25 WTO WTO
WTO WTO WTO WTO WTO WTO WTO WTO WTO WTO WTO WTO WTO 26
WTO () 144 WTO ()WTO WTO rule-based WTO () WTO 27
() WTO WTO WTO WTO WTO WTO () WTO WTO WTO WTO WTO WTO 28
29 WTO WTO WTO WTO WTO
cgmp 2002 2001 2001 1860 1865 Maxwell 1872 Makay 1895 1897 1070 1899 1945 30
2800 1945 20 1997 1945 1945 20 1954 1545 Chi1996 1958 1966 1966 1984 1988 1991 1998 1998 31
50 1955 1956 56 62 50 50 1956 1966 21 10155 7100 32
33 2046 1995 1966 1976 300 129 1997 1978 23
30 23 1975~1980 117 1000 1995 1986 1988 1988 2000 25 10 0.42 0.14 2000 702000 126000 4000 5000 34
35 4000 5000 500 600 1997
36 CT
37 Secondary Analysis Approach 1997 Expert interview
SWOT SWOT 3-1 38
WTO SWOT 3-1 39
37 1 2 6 80 51 43 8 29 80 15000 10 3 10 44 20 ( 4 )96 3 167 1 1976 40 210 147 70% 40
41,,,,,,,, 125 15 4.2 1993 6 1996 11
1995 11 1 1994 8 1998 2010 1.6 60 640 310 1997 1995 42
500 2000 11 14 12 2001 12 2002 1 1 43
44 30.5 28.6 27.0 30.2 31.8 31.8 44 2544
45 59 4000 WTO () WTO GATS 2002 1 1. 2. 2
46 3 4 1. 2. WTO
47 1 GATS WTO WTO WTO GATS WTO
48 2 WTO 90 4 1 2 902002 1,369 90 2001 5000
WTO () (2001) 22 12 1992 2000 2003 WTO 49
3.6 2,250 16,100 GDP 5.3% 11 4 7 30,562 Doctor to Population Ratio 1750 13.64 3,979 1.78 593 44 127,676 57 9,425 2,544 2001 50
() () () 47 55 85 385 87 50 392 51
94 6 () 73 50 81 100 200 100 100 4-1 1966~1995 7 120 1996~ 8 120 1984~1991 5 50 1992~ 100 1998~ 8 50 52
4-2 (91 ) 102 108 97 98 97 120 108 730 100 98 99 102 93 - - 492 47 46 47 47 38 - - 225 (87 ) 91 1 16 53
45 4-1 54
55 5 2001 5
56
4-3 2000 2682 2187 & 2108 857 720 45 281 61 17576 3032 8904 3733 57
4-2 58
59 1. 2. 3. 4. 5. 6. 7. 1. 2. GMP 3. 337, 200 4. 5. 6. 7. 8. 9.
10. 11. HPLC 12. 13. 14. 15. 16. 103 1. 2. 1. 2. 3. 4. 5. 60
61
1.78 3,979 (4-4) 2.2 2002 2000 7 1 2003 2001 4-4 2,633,802 555 21.1 1,494,457 263 17.6 3,610,252 572 15.8 465,799 46 9.9 1,762,963 273 15.5 446,300 40 9.0 560,640 73 13.0 1,502,274 351 23.4 1,313,994 243 18.5 541,818 92 17.0 743,562 85 11.4 563,365 43 7.6 1,107,397 130 11.7 62
1,236,958 166 13.4 909,364 121 13.3 244,612 18 7.4 353,139 40 11.3 92,268 4 4.3 390,966 53 13.6 373,296 72 19.3 983,694 494 50.2 267,993 80 29.9 740,846 163 22.0 56,958 2 3.5 2,633,802 - - 22,405,568 3,979 17.8 2001 6 6 180 44 2 42 2544 63
3,979 2002 960 12.9 3,852 GDP 2.5% 32 (4 ) 1 64
337.7 1380 13.2 33.4 14,164 2,682 720,795 279,622 23.9WHO2002 2002 1 2 51 2 8 51260 18600 30 3 41336 14000 1 65
66
40 160 160 160 160 60 12 70% 12 3 67
4-5 234 2.5 34 34 3 34 34 4 3 4 34 3 3 1997 72-88 68
69 4-6 34 3 34 34 234 4 34 34 4 3 1997 72-88 2 1956
70 1958 32 2 1 1 12
71 1998 199951 4 6
72 1 1 2
73 5 11998630 220031231 3 5 2002 2001
74 1993 (1) (2) (3) 450-600 15-25% 65-75% 5% (1) (2) (3) 300-450 15-25% 65-75% 5% 1999
75
50 1954 1956 58 1986 1988 1. 2. 76
77 3. 4. 5. 6. 7. 8.
9. 10. 11. 12. 78
79 4-3
80 12 3
2001 498888 334034 14938 160 1999 2001 2682 65 135 279622 2001 1.9 422 81
82 SWOT SWOT 4-7 strengths
() 60 1~3 2 1 1999 5 1 5060 1999 83
weakness () () () () 84
85 7 ()
() () 2001 () ( 2000) 35~40 70~80 86
87 () 1997 8 1998 7.5%4.5% 1.5%2.1% 5.81% 98 2001 2001 2011
( ) 1997 5 2002 opportunities 88
89 WHO WTO WTO
90 WTO threats
91?? 1990 1990 1989 1983 20~30 5~10
WTO 4,000 12,000 20012002 1,369.. 92-97 2% 8788 89 4.3%5.82%7% 92
4-7 SWOT WTO WTO 93
94 WTO SWOT Weihrich SWOT WT
95
96 1988 6 29
97 (clinical trial) 2002 8 WO 70%
98
99 SO WTO
1. Chi C., JL Lee, JS. Lai, CY Chen, SK Chang, SC Hen.1996,"The practice of Chinese medicine in Taiwan". Social Science & Medicine, Vol.43,No.9, p.1329-1348 2. Porter, M. E.1979,"How Competence Forces Shape Strategy". Harvard Business Review, March- April. 3. Porter, M. E.1985,Competitive Strategy, New York: The Free Press. 4. Barney. D.F.1991,"Tine paths in the diffusion of Product Innovations". Macmillan, London. p.100 5. Weihrich H.1982,"The TOWS Matrix-A Tool for Situational Analysis". Long Range PlanningVol.15,No.2, p.60 6. Ansoff. I. H.1988, The New Corporate Strategy,3 rd ed., New York NJohn Wiley & Sons, Inc., p.83 7. Chi C., JL Lee, JS. Lai, CY Chen, SK Chang, SC Hen.1996,"The practice of Chinese medicine in Taiwan". Social Science & Medicine, Vol.43,No.9, p.1329-1348 8. Hesketh, T., WX. Zhu, JE. Ultmann.1997"Health in China. Traditional Chinese medicineone country, two systems". BMJ,Vol.315,No.7100, p.115-117 9. Ken C..1995"The Role of Tradition Medicine and WHO S Program 100
on Traditional Medicine".The 8th INT L Congress of Oriental Medicine, p.27-39 1. Michael Quinn Patton 1995 2. Anselm StraussJuliet Corbin 1997 3. George Luffman Edward Lea Stuart Stuart SanderswonBrian Kenny 2001 4. Charles W.L. Hill Gareth R. Jones 1996 5. 1993 6. 2001 7. 1997 8. 1984 9. 1997 10. Leslie W. Rue Lloyd L. Byars 2000 101
11. 405 35 12. 1997 13. 1995 14. 1987 7 3 15. 2000 SWOT 32 26-28 16. 1995 6 2 75-91 17. 1995 540 37-39 18. 2001 ECM 20 6 56-57 19. 2001 7 2 75-83 20. 2001 102
12 4 231-242 21. 2003 86-92 22. 1990 26 3 153-160 23. 1997 6 3 179-186 24. 1995 225 8-12 25. 1990 1 1 58-66 26. 1990 17 2 136-142 27. 2002 ECM 21 1 41-42 28. 2002 103
ECM 21 5 27-30 29. 2002 WTO ECM 21 2 58-59 30. 2002 ECM 21 3 9-12 31. 1997 5 4 72-88 32. 1996 7 3 181-185 33. 2002 34. 1994 35. 1990 36. 2001 37. 1993 104
38. 2000 39. 2002 22 4 40. 1989 114 41. 1997 16 1 42. 2001 WTO 43. 2001 WTO 44. 2002 21 16 1 7-10 45. 2001 7 2 68-74 46. 2000 47. 1999 48. 2002 105
49. 1999 50. 1999 51. http//www.trade.gov.tw/ 52. http://www.doh.gov.tw/statistic/ 53. http//www.uncma.org.tw/ 54. http//www.ccmp.gov.tw/ 55. http//www.satcm.gov.cn/ 56. http://big5.itcmedu.com/yls/hwzyy_03.html/ 57. http://www.moex.gov.tw/ 58. 107 http://www.taconet.com.tw/jus107/ 106